36Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Croatia
Neuroscience Intelligence
Croatia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #50 of 50 · Data maturity A · Research score 24.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:35 UTC.
6Recruiting trials
4Publications
11Institutions
Executive interpretation
Croatia ranks #50 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Otsuka Pharmaceutical Development & Commercialization, Inc.20 recruiting
Xenon Pharmaceuticals Inc.21 recruiting
Klinički Bolnički Centar Zagreb21 recruiting
Novo Nordisk A/S20 recruiting
TauRx Therapeutics Ltd20 recruiting
Celgene20 recruiting
AbbVie20 recruiting
Eisai Limited20 recruiting
Hoffmann-La Roche20 recruiting
Bristol-Myers Squibb11 recruiting
Disease activity
Epilepsy9trials
Alzheimers8trials
Schizophrenia2trials
Multiple Sclerosis2trials
Movement Disorders1trials
Neuro Oncology1trials
Neuromuscular1trials
Other Neurology1trials
Pain Neuropathy1trials
Parkinsons1trials
Research institutions
Institute for Anthropological ResearchOpenAlexlinked institution
Ericsson (Croatia)OpenAlexlinked institution
University Hospital for Infectious Diseases "Dr Fran Mihaljevic"OpenAlexlinked institution
Andrija Stampar Teaching Institute of Public HealthOpenAlexlinked institution
University of ZagrebOpenAlexlinked institution
Gen-infoOpenAlexlinked institution
University Hospital Centre ZagrebOpenAlexlinked institution
University of RijekaOpenAlexlinked institution
University of SplitOpenAlexlinked institution
Sisters of Charity HospitalOpenAlexlinked institution
Clinical evidence trail
NCT07384845The Role of Transcutaneous Vagus Nerve Stimulation in Treatment of Acute Brain InjuryNOT_YET_RECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06493812Comparison of Clinical Value in the Use of the Fascia Lata and Temporal Muscle Fascia in the Reconstruction of the Dura in the Sellar RegionRECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT06282003Protective Anesthesiological Management Procedure Imposes Control on Respiratory ComlicationsUNKNOWN
NCT05695950A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisCOMPLETED
Research evidence trail
PUBMEDTwo dopaminergic systems, one bladder: recognising a therapy-resistant urinary phenotype in Parkinson's disease.2026-10-01
PUBMEDSensory Abnormalities and Pain in the Donor Sites of Radial Forearm and Fibula Free Flaps-A Systematic Review.2026-08-18
PUBMEDDeprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence.2026-01-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.